10-Q: Jackson Acquisition Company II Reports Q3 2024 Financial Results Following IPO

Jackson Acquisition Company II, a healthcare-focused SPAC, files its first quarterly report since its inception and recent IPO, detailing formation activities and initial financial position.

Summary

• Jackson Acquisition Company II, a blank check company, was incorporated on September 11, 2024, aiming to complete a business combination.
• The company focuses on healthcare services, healthcare technology, or the broader healthcare industry.
• As of September 30, 2024, the company had not commenced operations and had a net loss of $49,568.
• On December 11, 2024, Jackson Acquisition Company II consummated its IPO, raising $230 million through the sale of 23,000,000 units at $10.00 per unit, including the full exercise of the underwriter's over-allotment option.
• Simultaneously with the IPO, the company sold 840,000 private placement units at $10.00 each, generating $8.4 million in gross proceeds.
• Transaction costs for the IPO amounted to $5,157,741.
• An amount of $232,300,000 from the IPO and private placement was placed in a trust account.
• The company has 24 months from the IPO to complete a business combination.
• If a business combination isn't completed within this period, the company will redeem public shares and liquidate.
• As of September 30, 2024, the company had no cash and a working capital deficit of $215,119.
• The company issued an unsecured promissory note to RJ Healthcare SPAC II, LLC, allowing borrowings up to $300,000; $120,368 was outstanding as of September 30, 2024.
• The company will pay the Sponsor $10,000 per month for office space and administrative support.
• The company is exposed to risks and uncertainties related to the Russia-Ukraine conflict and the Israel-Hamas conflict, which could affect its search for a business combination target.
• The company's management believes it has sufficient funds for working capital needs for at least one year from the issuance of the financial statements.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The company successfully completed its IPO, but it is still in the early stages and faces risks associated with finding and completing a business combination. The financial results reflect a pre-operational phase.

Positives

• The successful completion of the IPO on December 11, 2024, raised $230 million, providing substantial capital for pursuing a business combination.
• The company secured an additional $8.4 million through private placement units, further bolstering its financial resources.
• Management believes the company has sufficient funds for working capital needs for at least one year from the issuance of the financial statements.

Negatives

• As of September 30, 2024, the company had a net loss of $49,568 and a working capital deficit of $215,119.
• The company has not yet commenced operations and has not generated any revenues.
• The company is reliant on completing a business combination within 24 months, or it will be forced to liquidate.

Risks

• The company faces the risk of not being able to complete a business combination within the 24-month timeframe, leading to liquidation.
• Geopolitical instability, including the Russia-Ukraine conflict and the Israel-Hamas conflict, could adversely affect the company's search for a business combination target.
• The company's financial instruments are subject to credit risk, particularly concerning cash accounts exceeding FDIC coverage limits.
• The company is dependent on the Sponsor and its affiliates for loans to cover working capital deficiencies, which may not be available or sufficient.

Future Outlook

The company intends to complete a business combination within 24 months from the closing of the IPO, utilizing funds from the trust account and potentially issuing shares or incurring debt.

Industry Context

As a SPAC focused on the healthcare industry, Jackson Acquisition Company II operates in a sector with significant growth potential but also faces regulatory and market-specific risks. The company's success depends on its ability to identify and merge with a high-quality target business in the healthcare space.

Comparison to Industry Standards

• It is difficult to compare Jackson Acquisition Company II to industry standards at this early stage, as it is a newly formed SPAC with no operating history.
• Comparable companies would be other healthcare-focused SPACs, such as those sponsored by Deerfield Management or Foresite Capital, but their performance will depend heavily on the quality of their eventual business combinations.
• The $230 million raised in the IPO is a reasonable amount for a SPAC targeting the healthcare sector, but the ultimate success will depend on the valuation and performance of the acquired company.

Related Party Transactions

• The company issued 5,750,000 Class B ordinary shares to the Sponsor for $25,000.
• The company issued an unsecured promissory note to RJ Healthcare SPAC II, LLC, allowing borrowings up to $300,000.
• The company will pay the Sponsor $10,000 per month for office space and administrative support.
• The Sponsor transferred 200,000 Founder Shares to the Company's officers and directors at their original purchase price.

Stakeholder Impact

• Shareholders are subject to the risk of the company not completing a business combination within the specified timeframe, potentially leading to liquidation.
• Employees and management are focused on identifying and completing a business combination.
• The target business will be impacted by the terms and conditions of the business combination agreement.

Next Steps

• The company will continue to seek a target business for a potential business combination.
• The company will perform due diligence on prospective target businesses.
• The company will negotiate and complete a business combination within the 24-month timeframe.

Key Dates